Lake Street raised the firm’s price target on NeuroPace to $12 from $10 and keeps a Buy rating on the shares after having hosted Mark Richardson, a board-certified neurosurgeon and expert in drug-resistant epilepsy and the treatment options, including NeuroPace’s RNS system. The firm says the fireside chat with Dr. Richardson, “a well-known thought leader in the space,” strongly reaffirms its thesis that the RNS system can be the standard of care in drug-resistant epilepsy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NPCE:
- Lake Street medical devices analysts hold an analyst/industry conference call
- NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
- NeuroPace initiated with an Overweight at Cantor Fitzgerald
- NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
